alexa Identification of Glioma Stem Cells: What is Already Known and How Far do We Still Need to Go? The Biomarkers Dilemma
ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Identification of Glioma Stem Cells: What is Already Known and How Far do We Still Need to Go? The Biomarkers Dilemma

Paola Brescia#, Cristina Richichi#, and Giuliana Pelicci*

Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy

#Equally Contributed

*Corresponding Author:
Dr. Giuliana Pelicci
Department of Experimental Oncology
European Institute of Oncology (IEO), Milan, Italy
Tel: +390257489830
Fax: +390294375990
E-mail: [email protected]

Received date: July 05, 2011; Accepted date: August 04, 2011; Published date: August 08, 2011

Citation: Brescia P, Richichi C, Pelicci G (2011) Identification of Glioma Stem Cells: What is Already Known and How Far do We Still Need to Go? The Biomarkers Dilemma. J Carcinogene Mutagene S1:003. doi: 10.4172/2157-2518.S1-003

Copyright: © 2011 Brescia P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Cancer stem cells (CSCs) have been isolated in multiple tumour types and although the presence of surface markers selectively expressed on CSCs can be used to isolate these cells, no marker or pattern of markers are sufficiently robust to definitively identify CSCs. Several markers have been evaluated for their prognostic value with promising early results, however to date none has been proven to be clinically useful in large-scale studies. A major need exists to identify markers of CSCs for glioblastoma (GBM), which would yield new therapeutic interventions. Given the complex genetic and epigenetic heterogeneity of human GBMs, it is unlikely that the expression of a single marker will define CSCs in every tumour, hence a combination of markers will probably best define glioma tumour stem cells. The studies reported in the literature regarding the identification of specific cell surface markers involved in tumourigenic processes of the GBM tumour-initiating cells have been inconclusive. Further investigations are necessary to identify both CSC-specific markers and the molecular mechanism sustaining the tumourigenic potential of these cells in order to develop novel treatments to target this group of cells. Markers for GBM stem cells such as CD133, CD15, integrin α6, L1CAM, are available and might be informative to identify these cells but cannot be conclusively linked to a stem cell phenotype. Overlap of expression, functional state and morphology of different subpopulations lead us to reconsider, or carefully consider, the techniques employed so far to characterize cancer stem cells. Major effort might be exploited to look for alternative methods, to isolate CSCs independently from markers. Due to a dearth of methods and markers that reliably assay the function of candidate stem cells, the isolation/enrichment of tumoural stem cells to be therapeutically targeted remains a major challenge.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version